Stockscreener 앱 받기
7.24
5.24%
-0.40
시간 외 거래:
7.51
0.27
+3.73%
전일 마감가:
$7.64
열려 있는:
$7.69
하루 거래량:
74,760
Relative Volume:
0.54
시가총액:
$14.99M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-0.4733
EPS:
-15.2954
순현금흐름:
$-24.23M
1주 성능:
+6.20%
1개월 성능:
-39.25%
6개월 성능:
-58.04%
1년 성능:
-88.42%
1일 변동 폭
$6.88
$7.69
1주일 범위
$6.0101
$7.75
52주 변동 폭
$6.0101
$91.25
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MBRX
Moleculin Biotech Inc
|
7.24 | 15.96M | 0 | -29.77M | -24.23M | -15.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-09 | 재개 | H.C. Wainwright | Buy |
| 2025-02-12 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - GlobeNewswire Inc.
Geopolitics Watch: Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Reactions & Fast Momentum Entry Tips - BỘ NỘI VỤ
How supply shortages influence Moleculin Biotech Inc. (MOL) stockPortfolio Profit Report & Precise Swing Trade Alerts - Newser
Why Moleculin Biotech Inc. stock attracts global investors2025 Institutional Moves & Risk Controlled Swing Trade Alerts - Newser
Enterprise value to EBITDA ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Price to cash flow ratio of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Why analysts maintain buy rating on Moleculin Biotech Inc. (MOL) stockGDP Growth & Reliable Momentum Entry Alerts - Newser
Number of employees of Moleculin Biotech, Inc. – MUN:MOL0 - TradingView
Moleculin Biotech, Inc. Financial Statements – FWB:MOL0 - TradingView
Non-controlling/minority interest of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Diluted net income available to common stockholders of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Operating income of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Gross profit of Moleculin Biotech, Inc. – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Statistics – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Cash Flow – BER:MOL0 - TradingView
Moleculin Biotech, Inc. Balance Sheet – BER:MOL0 - TradingView
Moleculin Biotech: Dividend historical data and projections - MarketScreener
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018 - marketscreener.com
How forex fluctuations impact Moleculin Biotech Inc. (MOL) stockWeekly Trend Report & Accurate Intraday Trading Signals - Newser
MBRX Stock Reverse Split 2025 Amid Biotech Bankruptcies: Analysts Remain Bullish - Bitget
Why Did MBRX Stock Plummet Over 25% Today? - MSN
Moleculin Biotech files for stock and warrants offering - MSN
Moleculin Biotech To Present Corporate Overview At Virtual Investor Closing Bell Series - Nasdaq
Will Moleculin Biotech Inc. stock rally after Fed decisionsJuly 2025 Patterns & Low Drawdown Trading Techniques - moha.gov.vn
Moleculin Biotech Bets Big On New Cancer Drug Trials - Finimize
Why Moleculin Biotech Inc. stock remains a top recommendationJuly 2025 Review & Free High Return Stock Watch Alerts - BỘ NỘI VỤ
Why Moleculin Biotech Inc. stock is considered a top pick2025 Fundamental Recap & Long-Term Investment Growth Plans - BỘ NỘI VỤ
Moleculin Biotech stock drops after announcing 1-for-25 reverse split - Investing.com
Moleculin Biotech announces 1-for-25 reverse stock split By Investing.com - Investing.com Nigeria
Moleculin Biotech Shares Slide After Announcing 1-for-25 Reverse Split - MSN
Moleculin Biotech falls after reverse stock split move - TradingView
Moleculin to Participate in the Virtual Investor Closing Bell Series - The Manila Times
Moleculin Biotech announces 1-for-25 reverse stock split - Investing.com
Moleculin Biotech, Inc. Announces 1-for-25 Reverse Stock Split Effective December 1, 2025 - Quiver Quantitative
Moleculin Announces Reverse Stock Split - marketscreener.com
Moleculin Biotech (Nasdaq: MBRX) Reverse Split to Cut Shares from 51.7M to 2.1M - Stock Titan
Moleculin Biotech Reports Increased Loss Amid Ongoing Trials - MSN
Moleculin Biotech Releases Corporate Presentation Update - TipRanks
Pre Market Movers: OSCR, NITO, CLSD Set The Pace - RTTNews
Moleculin Biotech receives Nasdaq delisting notice, plans to appeal By Investing.com - Investing.com Nigeria
Moleculin Biotech receives Nasdaq delisting notice, plans to appeal - Investing.com
Moleculin Biotech Appeals Nasdaq Delisting Decision - TipRanks
[8-K] Moleculin Biotech, Inc. Reports Material Event | MBRX SEC FilingForm 8-K - Stock Titan
Moleculin Biotech Releases New Corporate Presentation - MSN
Why analysts remain bullish on Moleculin Biotech Inc. stockDividend Hike & Daily Chart Pattern Signal Reports - newser.com
Is Moleculin Biotech Inc. (MOL) stock positioned for digital growth eraChart Signals & Stock Timing and Entry Methods - newser.com
Market reaction to Moleculin Biotech Inc.’s recent newsWeekly Trade Summary & Safe Entry Momentum Tips - newser.com
Published on: 2025-11-20 06:00:51 - newser.com
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Moleculin Biotech Inc 주식 (MBRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| KLEMP WALTER V | CEO and President |
Jun 23 '25 |
Buy |
0.37 |
675,675 |
250,000 |
743,607 |
1.44%
0.91%
자본화:
|
볼륨(24시간):